Anacor Pharmaceuticals Awarded $13.5M in Research Agreement with Defense Threat Reduction Agency

Anacor Pharmaceuticals

today announced it has entered into a research agreement with the United States Department of Defense, Defense Threat Reduction Agency (DTRA) to design and discover new classes of systemic antibiotics. A drug discovery consortium formed by Anacor, Colorado State University (C.S.U.) and the University of California at Berkeley (U.C. Berkeley) will conduct the research over a three and a half year period. The work is funded by a $13.5 million award from DTRA's R&D Innovation and Systems Engineering Office which was established to search for and execute strategic investments in innovative technologies for combating weapons of mass destruction. “Increasing resistance to existing antibiotics has created a critical need for new